• Profile

Real-life impact of the immunological tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study

Journal of the American Academy of Dermatology Jan 27, 2022

Researchers assessed the real-life effect of the immunological-based decision of treatment cessation (TC) on the 3 and 6-month relapse rate following TC in bullous pemphigoid. They found that 3 and 6-month relapse rate was not significantly decreased with TC decision depending on findings of ITs (immunological tests) vs a classical clinical-based decision.

  • In this retrospective multicentric study of 238 patients followed almost 6 months after TC, participants were grouped based on if the TC decision was in accordance with the results of ITs conducted during the 3 months before TC, despite the results of ITs or without ITs done.

  • Relapse occurred in 36 patients at 3 months post-TC: 14/95 of patients with TC in accordance with IT results (14.7%), 5/21 with TC despite ITs (23.8%) and 17/122 with TC without ITs (13.9%).

  • The relapse rate 6 months post-TC were 18.9%, 28.6%, and 18.9%, respectively, in the 3 groups.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen